Sign in
WithdrawnPhase 2

Branched-chain Amino Acid Supplementation for Hepatocellular Carcinoma

Key facts

Who runs it
Louisiana State University Health Sciences Center in New Orleans
Where
New Orleans, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 2
Started
1 Jun 2021
Ended
30 Dec 2023
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Branch Chain Amino Acid
  • maltodextrin
Record updated
28 January 2022
Why it stopped
Dr. Marshall left UMC and LSU Health Sciences Center.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (16)Hide the full registry criteria

Who can take part

  • Have been diagnosed with HCC and deemed a candidate for nonsurgical local therapy (TACE and/or percutaneous ablation)
  • Have a Child-Pugh score < 6
  • Are at least 18 years of age or older
  • Otherwise healthy adults
  • Provide written consent to participate

Who cannot take part

  • Are currently taking insulin or metformin
  • Have a diagnosis of renal failure
  • Have been diagnosed with branched-chain ketoaciduria (maple syrup urine disease)
  • Have been diagnosed with a medical condition that warrants a low-protein diet
  • Younger than 18 years of age
  • Have a Child-Pugh score > 6
  • Consume > 60g alcohol intake per day
  • Have hepatic encephalopathy
  • Pregnant women
  • Are unable to provide consent
  • Are incarcerated

Where in United States

  • University Medical Center New OrleansNew Orleans, United States

About the trial

What the trial wants to find out

Hepatocellular carcinoma (HCC) is the fifth most common cause of cancer death among men. While several new treatment options have recently become available, they are costly and have a potential for significant, adverse side effects. Many patients diagnosed with HCC also suffer from underlying liver disease, including cirrhosis. As many as 80-90% of patients diagnosed with HCC also have cirrhosis. Protein-energy malnutrition (PEM) in cirrhosis is as high as 65-90% and significantly increases the risk of morbidity and mortality as well as decreased quality of life.

Read full original descriptionShow less

Branched-chain amino acid (BCAA) supplementation has been extensively studied for usefulness in liver disease, specifically to treat hepatic encephalopathy to and preserve and restore muscle mass. Maintenance of liver function and prevention of PEM are essential for improving outcomes in patients with HCC. Branched-chain amino acid supplementation in HCC has been studied extensively in China \& Japan with multiple studies showing improvements in liver function, progression-free survival, and overall survival. Additionally, patients in treatment groups have shown improvement in quality of life indicators. However, these results have yet to be replicated in the United States. Branched-chain amino acid supplementation may be a safe, low-cost approach to improve survival, liver function indicators, and quality of life for patients diagnosed with HCC.

In this study, patients with primary HCC will be randomized to either a treatment group, which will receive standard of care and BCAA supplement or to a control group which will receive standard of care and a maltodextrin placebo. Both groups will receive liver-directed therapy including transarterial chemoembolization (TACE) and thermal ablation. All patients will complete a quality of life survey (FACT-Hep) at each visit.

The 2 groups in the trial

  • Control GroupPlacebo, for comparison

    The control group will receive current standard of care (locoregional therapy of the liver, serial bloodwork and imaging, serial assessments in clinic), consume a maltodextrin placebo supplement beginning two weeks prior to liver directed therapy and continue supplementation for the following 12 months.

    Treatment: maltodextrin

  • Intervention GroupTreatment being tested

    In the intervention group, patients will receive current standard of care (locoregional therapy of the liver, serial bloodwork and imaging, serial assessments in clinic) and consume BCAA supplements beginning two weeks prior to liver directed therapy and continue supplementation for the following 12 months.

    Treatment: Branch Chain Amino Acid

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Impact of Branched-chain Amino Acid Supplementation on Quality of Life and Overall Survival in Patients Receiving Liver Directed Therapy for Hepatocellular Carcinoma
Record updated
28 January 2022